Cat. No.: DAB-0012361
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala200 of human nSMase1. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SMPD2 |
| UniProt No. | O60906 |
| Gene ID | 6610 |
| Gene Description | Sphingomyelinases catalyze the hydrolysis of sphingomyelin to produce ceramide and phosphocholine. Ceramide is an important bioactive lipid triggering signal transduction involved in cell proliferation, apoptosis and differentiation. A number of SMases have been described and categorized based on their optimum pH activity, cation dependence, tissue distribution, and subcellular localization. These include a lysosomal acid SMase, a Zn++-dependent secreted acid SMase, a membrane-bound Mg++-dependent neutral SMase, a Mg++-independent neutral SMase, and an alkaline SMase.nSMase1 is a Mg++-dependent neutral SMase that is widely expressed and predominantly localized to the endoplasmic reticulum. This protein has also been shown to have lyso-platelet activating factor phospholipase C activity. A second neutral SMase, nSMase2 is predominantly expressed in the brain. The activity of neutral SMases is regulated by oxidative stress, chemotherapeutic drugs, inflammatory cytokines, and apoptotic stimuli. Analysis of single and double knockouts of the SMPD2 and SMPD3 has revealed that loss of both genes leads to complete loss of neutral SMase activity with developmental defects observed with loss of nSMase2. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
